Results 61 to 70 of about 269,977 (355)
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Molecular Oncology, EarlyView.In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi +3 more
wiley +1 more source
Potential association factors for developing effective peptide-based cancer vaccines
Frontiers in Immunology, 2022 Peptide-based cancer vaccines have been shown to boost immune systems to kill tumor cells in cancer patients. However, designing an effective T cell epitope peptide-based cancer vaccine still remains a challenge and is a major hurdle for the application ...
Chongming Jiang +14 more
doaj +1 more source
Heat shock proteins may be a missing link between febrile infection and cancer tumor rejection via autoantigen molecular mimicry [PDF]
arXiv, 2023 Numerous epidemiological studies suggest febrile infections could confer long-term immunity to certain types of cancers, though the precise mechanisms for this phenomenon remain unclear. Systemic heat-shock responses to fever may be key to understanding the overlapping outcomes of immune responses to infection and cancer. To investigate this hypothesis,
arxiv
Cancer Vaccines: A Ray of Hope [PDF]
, 2014 In lieu of an abstract, here are the article\u27s first two paragraphs: Recent cancer statistics review by Surveillance, Epidemiology, and End Results (SEER) Program by National Cancer Institute (NCI) shows that cancer is the second most leading cause of
Chablani, Lipika
core +1 more source
Molecular Oncology, EarlyView.CircCCNB1 expression is down‐regulated in nasopharyngeal carcinoma (NPC); thus, less NF90 protein is bound to circCCNB1 and more binds to pri‐miRNAs, blocking their (pri‐miRNAs) binding to DGCR8 and inhibiting the processing and generation of miR‐15b‐5p/miR‐7‐1‐3p. Furthermore, decreased miR‐15b‐5p/miR‐7‐1‐3p promotes the expression of the target genes
Chunmei Fan +6 more
wiley +1 more source
Cell, 2014 This SnapShot illustrates the main concepts and underlying biology of therapeutic vaccination in cancer. Dendritic cells (DCs) are an essential component of vaccination through their capacity to capture, process, and present antigens to T cells. We have come a long way in our understanding of what is needed to elicit therapeutic immunity when cancer ...
Palucka, Karolina, Banchereau, Jacques
openaire +4 more sources
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
HTLV-1 p13 Protein Hijacks Macrophage Polarization and Promotes T-Cell Recruitment
VirusesThe human T-cell leukemia type-1 (HTLV-1) retrovirus establishes chronic life-long infection in a fraction of infected individuals associated with severe pathological conditions. Although the mechanism driving disease development is not fully understood,
Ramona Moles +11 more
doaj +1 more source
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Military Medical Research, 2022 Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity, especially in genetic alteration and microenvironment. Conventional therapeutic strategies for pancreatic cancer usually suffer resistance, highlighting the necessity ...
Xing Huang +4 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Cancer vaccines represent among the most promising strategies in the battle against cancers. However, the clinical efficacy of current cancer vaccines is largely limited by the lack of optimized delivery systems to generate strong and persistent ...
Lu Han +6 more
doaj +1 more source